

you search for your invoice, click “Pay Now” to be redirected to *Pay.gov*. Electronic payment options are based on the balance due. Payment by credit card is available for balances that are less than \$25,000. If the balance exceeds this amount, only the ACH option is available. Payments must be made using U.S. bank accounts as well as U.S. credit cards.

If a check, bank draft, or postal money order is submitted, make it payable to the order of the Food and Drug Administration and include the user fee ID number to ensure that the payment is applied to the correct fee(s). Payments can be mailed to: Food and Drug Administration, P.O. Box 979108, St. Louis, MO 63197–9000. If a check, bank draft, or money order is to be sent by a courier that requests a street address, the courier should deliver your payment to: U.S. Bank, Attention: Government Lockbox 979108, 1005 Convention Plaza, St. Louis, MO 63101. (Note: This U.S. Bank address is for courier delivery only. If you have any questions concerning courier delivery, contact U.S. Bank at 314–418–4013. This telephone number is only for questions about courier delivery.) Please make sure that the FDA post office box number (P.O. Box 979108) and ID number is written on the check, bank draft, or postal money order.

For payments made by wire transfer, include the unique user fee ID number to ensure that the payment is applied to the correct fee(s). Without the unique user fee ID number, the payment may not be applied. The originating financial institution may charge a wire transfer fee. Include applicable wire transfer fees with payment to ensure fees are fully paid. Questions about wire transfer fees should be addressed to the financial institution. The following account information should be used to send payments by wire transfer: U.S. Department of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Acct. No.: 75060099, Routing No.: 021030004, SWIFT: FRNYUS33. FDA’s tax identification number is 53–0196965.

B. Annual BPD and Program Fees

FDA will issue invoices with payment instructions for FY 2021 annual BPD and program fees under the new fee schedule in August 2020. Payment will be due on October 1, 2020. If sponsors join the BPD program after the annual BPD invoices have been issued in August 2020, FDA will issue invoices in December 2020 to firms subject to fees for FY 2021 that qualify for the annual BPD fee after the August 2020 billing. FDA will issue invoices in December

2020 for any annual program fees for FY 2021 that qualify for fee assessments and were not issued in August 2020.

Dated: July 29, 2020.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2020–16858 Filed 7–30–20; 4:15 pm]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2020–N–1693]

Outsourcing Facility Fee Rates for Fiscal Year 2021

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the fiscal year (FY) 2021 rates for the establishment and re-inspection fees related to entities that compound human drugs and elect to register as outsourcing facilities under the Federal Food, Drug, and Cosmetic Act (FD&C Act). The FD&C Act authorizes FDA to assess and collect an annual establishment fee from outsourcing facilities, as well as a re-inspection fee for each re-inspection of an outsourcing facility. This document establishes the FY 2021 rates for the small business establishment fee (\$5,695), the non-small business establishment fee (\$18,837), and the re-inspection fee (\$17,085) for outsourcing facilities; provides information on how the fees for FY 2021 were determined; and describes the payment procedures outsourcing facilities should follow. These fee rates are effective October 1, 2020, and will remain in effect through September 30, 2021.

FOR FURTHER INFORMATION CONTACT:

For more information on human drug compounding and outsourcing facility fees: Visit FDA’s website at: <https://www.fda.gov/Drugs/Guidance/ComplianceRegulatoryInformation/PharmacyCompounding/default.htm>.

For questions relating to this notice: Lola Olajide, Office of Financial Management, Food and Drug Administration, 4041 Powder Mill Rd., Rm. 61077B, Beltsville, MD 20705–4304, 240–402–4244.

SUPPLEMENTARY INFORMATION:

I. Background

The Drug Quality and Security Act contains important provisions relating to the oversight of compounding human

drugs. Title I of this law, the Compounding Quality Act, created a new section 503B in the FD&C Act (21 U.S.C. 353b). Under section 503B of the FD&C Act, a human drug compounder can become an “outsourcing facility.”

Outsourcing facilities, as defined in section 503B(d)(4) of the FD&C Act, are facilities that meet all of the conditions described in section 503B(a), including registering with FDA as an outsourcing facility and paying an annual establishment fee. If the conditions of section 503B are met, a drug compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility is exempt from three sections of the FD&C Act: (1) Section 502(f)(1) (21 U.S.C. 352(f)(1)) concerning the labeling of drugs with adequate directions for use; (2) section 505 (21 U.S.C. 355) concerning the approval of human drug products under new drug applications (NDAs) or abbreviated new drug applications (ANDAs); and (3) section 582 (21 U.S.C. 360eee–1) concerning drug supply chain security requirements. Drugs compounded in outsourcing facilities are not exempt from the requirements of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)) concerning current good manufacturing practice requirements for drugs.

Section 744K of the FD&C Act (21 U.S.C. 379j–62) authorizes FDA to assess and collect the following fees associated with outsourcing facilities: (1) An annual establishment fee from each outsourcing facility and (2) a re-inspection fee from each outsourcing facility subject to a re-inspection (see section 744K(a)(1) of the FD&C Act). Under statutorily defined conditions, a qualified applicant may pay a reduced small business establishment fee (see section 744K(c)(4) of the FD&C Act).

FDA announced in the **Federal Register** of November 24, 2014 (79 FR 69856), the availability of a final guidance for industry entitled “Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act.” The guidance provides additional information on the annual fees for outsourcing facilities and adjustments required by law, re-inspection fees, how to submit payment, the effect of failure to pay fees, and how to qualify as a small business to obtain a reduction of the annual establishment fee. This guidance can be accessed on FDA’s website at: <https://www.fda.gov/media/136683/download>.

II. Fees for FY 2021**A. Methodology for Calculating FY 2021 Adjustment Factors****1. Inflation Adjustment Factor**

Section 744K(c)(2) of the FD&C Act specifies the annual inflation adjustment for outsourcing facility fees. The inflation adjustment has two components: One based on FDA's

payroll costs and one based on FDA's non-payroll costs for the first 3 of the 4 previous fiscal years. The payroll component of the annual inflation adjustment is calculated by taking the average change in FDA's per-full time equivalent (FTE) personnel compensation and benefits (PC&B) in the first 3 of the 4 previous fiscal years (see section 744K(c)(2)(A)(ii) of the FD&C Act). FDA's total annual spending

on PC&B is divided by the total number of FTEs per fiscal year to determine the average PC&B per FTE.

Table 1 summarizes the actual cost and FTE data for the specified fiscal years, and provides the percent change from the previous fiscal year and the average percent change over the first 3 of the 4 fiscal years preceding FY 2021. The 3-year average is 1.2644 percent.

TABLE 1—FDA PC&Bs EACH YEAR AND PERCENT CHANGE

Fiscal year	2017	2018	2019	3-Year average
Total PC&B	\$2,581,551,000	\$2,690,678,000	\$2,620,052,000
Total FTE	17,022	17,023	17,144
PC&B per FTE	\$151,660	\$158,061	\$152,826
Percent change from previous year	2.8845%	4.2206%	–3.3120%	1.2644%

Section 744K(c)(2)(A)(ii) of the FD&C Act specifies that this 1.2644 percent should be multiplied by the proportion

of PC&B to total costs of an average FDA FTE for the same 3 fiscal years.

TABLE 2—FDA PC&Bs AS A PERCENT OF FDA TOTAL COSTS OF AN AVERAGE FTE

Fiscal year	2017	2018	2019	3-Year average
Total PC&B	\$2,581,551,000	\$2,690,678,000	\$2,620,052,000
Total Costs	\$5,104,580,000	\$5,370,935,000	\$5,663,389,000
PC&B Percent	50.5732%	50.0970%	46.2630%	48.9777%

The payroll adjustment is 1.2644 percent multiplied by 48.9777 percent, or 0.6193 percent.

Section 744K(c)(2)(A)(iii) of the FD&C Act specifies that the portion of the inflation adjustment for non-payroll costs for FY 2021 is equal to the average annual percent change in the Consumer Price Index (CPI) for urban consumers

(U.S. City Average; Not Seasonally Adjusted; All items; Annual Index) for the first 3 years of the preceding 4 years of available data, multiplied by the proportion of all non-PC&B costs to total costs of an average FDA FTE for the same period.

Table 2 provides the summary data for the percent change in the specified

CPI for U.S. cities. These data are published by the Bureau of Labor Statistics and can be found on its website: <https://data.bls.gov/cgi-bin/surveymost?cu>. The data can be viewed by checking the box marked “U.S. city average, All items—CUUR0000SA0” and then selecting “Retrieve Data.”

TABLE 3—ANNUAL AND 3-YEAR AVERAGE PERCENT CHANGE IN U.S. CITY AVERAGE CPI

Year	2017	2018	2019	3-Year average
Annual CPI	245.120	251.107	255.657
Annual Percent Change	2.1304%	2.4425%	1.8120%	2.1283%

Section 744K(c)(2)(A)(iii) of the FD&C Act specifies that this 2.1283 percent should be multiplied by the proportion of all non-PC&B costs to total costs of an average FTE for the same 3 fiscal years. The proportion of all non-PC&B costs to total costs of an average FDA FTE for FYs 2017 to 2019 is 51.0223 percent (100 percent – 48.9777 percent = 51.0223 percent). Therefore, the non-pay adjustment is 2.1283 percent times 51.0223 percent, or 1.0859 percent.

The PC&B component (0.6193 percent) is added to the non-PC&B component (1.0859 percent), for a total inflation adjustment of 1.7052 percent (rounded). Section 744K(c)(2)(A)(i) of

the FD&C Act specifies that one is added to that figure, making the inflation adjustment 1.017052.

Section 744K(c)(2)(B) of the FD&C Act provides for this inflation adjustment to be compounded after FY 2015. This factor for FY 2021 (1.7052 percent) is compounded by adding one to it, and then multiplying it by one plus the inflation adjustment factor for FY 2020 (11.9895 percent), as published in the **Federal Register** on July 31, 2019 (84 FR 37311 at 37312). The result of this multiplication of the inflation factors for the 6 years since FY 2015 (1.017052 × 1.119895) becomes the inflation adjustment for FY 2021. For FY 2021,

the inflation adjustment is 13.8991 percent (rounded). We then add one, making the FY 2021 inflation adjustment factor 1.138991.

2. Small Business Adjustment Factor

Section 744K(c)(3) of the FD&C Act specifies that in addition to the inflation adjustment factor, the establishment fee for non-small businesses is to be further adjusted for a small business adjustment factor. Section 744K(c)(3)(B) of the FD&C Act provides that the small business adjustment factor is the adjustment to the establishment fee for non-small businesses that is necessary to achieve total fees equaling the

amount that FDA would have collected if no entity qualified for the small business exception in section 744K(c)(4) of the FD&C Act. Additionally, section 744K(c)(5)(A) states that in establishing the small business adjustment factor for a fiscal year, FDA shall provide for the crediting of fees from the previous year to the next year if FDA overestimated the amount of the small business adjustment factor for such previous fiscal year.

Therefore, to calculate the small business adjustment to the establishment fee for non-small businesses for FY 2021, FDA must estimate: (1) The number of outsourcing facilities that will pay the reduced fee for small businesses for FY 2021 and (2) the total fee revenue it would have collected if no entity had qualified for the small business exception (*i.e.*, if each entity that registers as an outsourcing facility for FY 2021 were to pay the inflation-adjusted fee amount of \$17,085).

With respect to (1), FDA estimates that 15 entities will qualify for small business exceptions and will pay the reduced fee for FY 2021. With respect to (2), to estimate the total number of entities that will register as outsourcing facilities for FY 2021, FDA used data submitted by outsourcing facilities through the voluntary registration process, which began in December 2013. Accordingly, FDA estimates that 85 outsourcing facilities, including 15 small businesses, will be registered with FDA in FY 2021.

If the projected 85 outsourcing facilities paid the full inflation-adjusted fee of \$17,085, this would result in total revenue of \$1,452,225 in FY 2021 ($\$17,085 \times 85$). However, 15 of the entities that are expected to register as outsourcing facilities for FY 2021 are projected to qualify for the small business exception and to pay one-third of the full fee ($\$5,695 \times 15$), totaling \$85,425 instead of paying the full fee ($\$17,085 \times 15$), which would total \$256,275. This would leave a potential shortfall of \$170,850 ($\$256,275 - \$85,425$).

Additionally, section 744K(c)(5)(A) of the FD&C Act states that in establishing the small business adjustment factor for a fiscal year, FDA shall provide for the crediting of fees from the previous year to the next year if FDA overestimated the amount of the small business adjustment factor for such previous fiscal year. FDA has determined that it is appropriate to credit excess fees collected from the last completed fiscal year, due to the inability to conclusively determine the amount of excess fees from the fiscal year that is in progress

at the time this calculation is made.

This crediting is done by comparing the small business adjustment factor for the last completed fiscal year, FY 2019 (\$2,248), to what would have been the small business adjustment factor for FY 2019 (\$1,560) if FDA had estimated perfectly.

The calculation for what the small business adjustment would have been if FDA had estimated perfectly begins by determining the total target collections ($15,000 \times [\text{inflation adjustment factor}] \times [\text{number of registrants}]$). For the most recent complete fiscal year, FY 2019, this was \$1,310,560 ($\$16,382 \times 80$). The actual FY 2019 revenue from the 80 total registrants (*i.e.*, 70 registrants paying FY 2019 non-small business establishment fee and 10 small business registrants) paying establishment fees is \$1,201,350. \$1,201,350 is calculated as follows: (FY 2019 Non-Small Business Establishment Fee adjusted for inflation only) \times (total number of registrants in FY 2019 paying Non-Small Business Establishment Fee) + (FY 2019 Small Business Establishment Fee) \times (total number of small business registrants in FY 2019 paying Small Business Establishment Fee). $\$16,382 \times 70 + \$5,461 \times 10 = \$1,201,350$. This left a shortfall of \$109,210 from the estimated total target collection amount ($\$1,310,560 - \$1,201,350$). \$109,210 divided by the total number of registrants in FY 2019 paying Standard Establishment Fee (70) equals \$1,560.

The difference between the small business adjustment factor used in FY 2019 and the small business adjustment factor that would have been used had FDA estimated perfectly is \$688 ($\$2,248 - \$1,560$). The \$688 (rounded to the nearest dollar) is then multiplied by the number of actual registrants who paid the standard fee for FY 2019 (70), which provides us a total excess collection of \$48,181 in FY 2019.

Therefore, to calculate the small business adjustment factor for FY 2021, FDA subtracts \$48,181 from the projected shortfall of \$170,850 for FY 2021 to arrive at the numerator for the small business adjustment amount, which equals \$122,669. This number divided by 70 (the number of expected non-small businesses for FY 2021) is the small business adjustment amount for FY 2021, which is \$1,752 (rounded to the nearest dollar).

B. FY 2021 Rates for Small Business Establishment Fee, Non-Small Business Establishment Fee, and Re-Inspection Fee

1. Establishment Fee for Qualified Small Businesses¹

The amount of the establishment fee for a qualified small business is equal to \$15,000 multiplied by the inflation adjustment factor for that fiscal year, divided by three (see section 744K(c)(4)(A) and (c)(1)(A) of the FD&C Act). The inflation adjustment factor for FY 2021 is 1.138991. See section II.A.1 for the methodology used to calculate the FY 2021 inflation adjustment factor. Therefore, the establishment fee for a qualified small business for FY 2021 is one third of \$17,085, which equals \$5,695 (rounded to the nearest dollar).

2. Establishment Fee for Non-Small Businesses

Under section 744K(c) of the FD&C Act, the amount of the establishment fee for a non-small business is equal to \$15,000 multiplied by the inflation adjustment factor for that fiscal year, plus the small business adjustment factor for that fiscal year, and plus or minus an adjustment factor to account for over- or under-collections due to the small business adjustment factor in the prior year. The inflation adjustment factor for FY 2021 is 1.138991. The small business adjustment amount for FY 2021 is \$1,752. See section II.A.2 for the methodology used to calculate the small business adjustment factor for FY 2021. Therefore, the establishment fee for a non-small business for FY 2021 is \$15,000 multiplied by 1.138991 plus \$1,752, which equals \$18,837 (rounded to the nearest dollar).

3. Re-Inspection Fee

Section 744K(c)(1)(B) of the FD&C Act provides that the amount of the FY 2021 re-inspection fee is equal to \$15,000, multiplied by the inflation adjustment factor for that fiscal year. The inflation adjustment factor for FY 2021 is 1.138991. Therefore, the re-inspection fee for FY 2021 is \$15,000 multiplied by 1.138991, which equals \$17,085 (rounded to the nearest dollar). There is

¹ To qualify for a small business reduction of the FY 2021 establishment fee, entities had to submit their exception requests by April 30, 2020. See section 744K(c)(4)(B) of the FD&C Act. The time for requesting a small business exception for FY 2021 has now passed. An entity that wishes to request a small business exception for FY 2022 should consult section 744K(c)(4) of the FD&C Act and section III.D of FDA's guidance for industry entitled "Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act," which can be accessed on FDA's website at <https://www.fda.gov/media/136683/download>.

no reduction in this fee for small businesses.

C. Summary of FY 2021 Fee Rates

TABLE 4—OUTSOURCING FACILITY FEES

Qualified Small Business Establishment Fee	\$5,695
Non-Small Business Establishment Fee	18,837
Re-inspection Fee	17,085

III. Fee Payment Options and Procedures

A. Establishment Fee

Once an entity submits registration information and FDA has determined that the information is complete, the entity will incur the annual establishment fee. FDA will send an invoice to the entity, via email to the email address indicated in the registration file, or via regular mail if email is not an option. The invoice will contain information regarding the obligation incurred, the amount owed, and payment procedures. A facility will not be registered as an outsourcing facility until it has paid the annual establishment fee under section 744K of the FD&C Act. Accordingly, it is important that facilities seeking to operate as outsourcing facilities pay all fees immediately upon receiving an invoice. If an entity does not pay the full invoiced amount within 15 calendar days after FDA issues the invoice, FDA will consider the submission of registration information to have been withdrawn and adjust the invoice to reflect that no fee is due.

Outsourcing facilities that registered in FY 2020 and wish to maintain their status as an outsourcing facility in FY 2021 must register during the annual registration period that lasts from October 1, 2020, to December 31, 2020. Failure to register and complete payment by December 31, 2020, will result in a loss of status as an outsourcing facility on January 1, 2021. Entities should submit their registration information no later than December 10, 2021, to allow enough time for review of the registration information, invoicing, and payment of fees before the end of the registration period.

B. Re-Inspection Fee

FDA will issue invoices for each re-inspection after the conclusion of the re-inspection, via email to the email address indicated in the registration file or via regular mail if email is not an option. Invoices must be paid within 30 days.

C. Fee Payment Procedures

1. The preferred payment method is online using electronic check (Automated Clearing House (ACH) also known as eCheck) or credit card (Discover, VISA, MasterCard, American Express). Secure electronic payments can be submitted using the User Fees Payment Portal at <https://userfees.fda.gov/pay>. (Note: Only full payments are accepted. No partial payments can be made online.) Once you search for your invoice, click “Pay Now” to be redirected to [Pay.gov](https://pay.gov). Electronic payment options are based on the balance due. Payment by credit card is available for balances less than \$25,000. If the balance exceeds this amount, only the ACH option is available. Payments must be made using U.S. bank accounts as well as U.S. credit cards.

2. If paying with a paper check: Checks must be in U.S. currency from a U.S. bank and made payable to the Food and Drug Administration. Payments can be mailed to: Food and Drug Administration, P.O. Box 979033, St. Louis, MO 63197-9000. Include invoice number on check. If a check is sent by a courier that requests a street address, the courier can deliver the check to: U.S. Bank, Attn: Government Lockbox 979033, 1005 Convention Plaza, St. Louis, MO 63101. (Note: This U.S. Bank address is for courier delivery only. If you have any questions concerning courier delivery, contact the U.S. Bank at 314-418-4013).

3. When paying by wire transfer, the invoice number must be included. Without the invoice number the payment may not be applied. Regarding re-inspection fees, if the payment amount is not applied, the invoice amount will be referred to collections. The originating financial institution may charge a wire transfer fee. If the financial institution charges a wire transfer fee, it is required that the outsourcing facility add that amount to the payment to ensure that the invoice is paid in full. Use the following account information when sending a wire transfer: U.S. Dept of the Treasury, TREAS NYC, 33 Liberty St., New York, NY 10045, Acct. No. 75060099, Routing No. 021030004, SWIFT: FRNYUS33. If needed, FDA's tax identification number is 53-0196965.

Dated: July 29, 2020.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2020-16856 Filed 7-30-20; 11:15 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Statement of Organization, Functions, and Delegations of Authority

July 7, 2020.

AGENCY: Office of the General Counsel, Office of the Secretary, HHS.

This document announces that the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services, Office of the General Counsel (OGC), is being amended to reflect a new component, changes in titles and order of succession, and changes in the law, and is being re-compiled so that the Statement of Organization incorporates all amendments, as may be amended herein, after the issuance of the last compiled Statement of Organization in 1973. See 38 FR 17,032 (June 28, 1973).

SUPPLEMENTARY INFORMATION: The Office of the Secretary (OS)'s Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services, Office of the General Counsel (OGC), should now read as follows:

Section I. Mission. The Mission of the Office of the General Counsel and the General Counsel, who is the special advisor to the Secretary on legal matters, is to provide all legal services and advice to the Secretary, Deputy Secretary, and all subordinate organizational components of the Department.

Section II. Organization. The Office of the General Counsel, under the supervision of a General Counsel, consists of:

1. The General Counsel and Immediate Office of the General Counsel
2. Divisions in the Office of the General Counsel
3. Ten Regional Offices

Subsection A. The Immediate Office of the General Counsel

1. The Immediate Office of the General Counsel. The Immediate Office of the General Counsel shall consist of the General Counsel, his or her executive assistant, a Principal Deputy General Counsel, such other Deputy General Counsel, both non-career and career, as the Secretary deems appropriate and appoints, Associate and Assistant Deputy General Counsel, Senior Counsel, and such other attorneys and assistants as the General Counsel deems appropriate, and the Office of Legal Resources (OLR).

a. The General Counsel. The General Counsel is the chief legal officer of the